Summary of Product Characteristics: Information for the User
Topiramate Cinfa 100 mg Film-Coated TabletsEFG
This medicine is subject to additional monitoring, which will facilitate the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this leaflet carefully before you start taking this medicine, because it contains important information for you
Topiramato cinfa belongs to a group of medicines called “antiepileptic medicines”. It is used for:
Make sure to read the patient guide that your doctor will give you.
A patient information card is provided with the packaging of topiramato cinfa to remind you of the risks during pregnancy.
If you are unsure if anything above applies to you, consult your doctor or pharmacist before using topiramato.
Warnings and precautions
Consult your doctor or pharmacist before starting to take topiramato cinfa if:
If you are unsure if anything above applies to you, consult your doctor before using topiramato cinfa.
If you have epilepsy, it is essential not to stop taking your medication without consulting your doctor first.
You must consult your doctor before taking any other medication containing topiramato that is given as an alternative to topiramato cinfa.
You may lose weight if you take topiramato, so your weight should be monitored regularly while taking this medication. If you lose too much weight or if a child taking this medication does not gain enough weight, you must consult your doctor.
A small number of people being treated with antiepileptic medications such as topiramato have had thoughts of self-harm or suicide. If you ever have these thoughts, contact your doctor immediately.
Topiramato may cause high levels of ammonia in the blood (seen in blood tests) which may cause a change in brain function, especially if you are also taking a medication called valproic acid or valproate sodium. Since this can be a serious condition, talk to your doctor immediately if you experience any of the following symptoms (see also section 4 “Possible side effects”):
-Difficulty thinking, remembering information, or solving problems
-Decreased state of alertness or consciousness
-Sensation of drowsiness with low energy
You may increase the risk of developing these symptoms at higher doses of topiramato.
Topiramato cinfa with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. Topiramato and certain medications may affect each other. Sometimes, the dose of one or both medications may need to be adjusted.
Especially inform your doctor or pharmacist if you are taking:
Tell your doctor if you change your menstrual bleeding while taking birth control pills and topiramato cinfa. You may experience irregular menstrual bleeding. In this case, continue taking the birth control pills and inform your doctor.
Keep a list of all the medications you take. Show this list to your doctor and pharmacist before starting a new medication.
Other medications that you should consult your doctor or pharmacist about include other antiepileptic medications, risperidone, lithium, hydrochlorothiazide, metformin, pioglitazone, glibenclamide, amitriptyline, propranolol, diltiazem, venlafaxine, flunarizine, St. John's Wort (Hypericum perforatum) (a herbal preparation used to treat depression), and warfarin used to prevent blood clotting.
If you are unsure if anything above applies to you, consult your doctor or pharmacist before taking topiramato.
Topiramato cinfa with food and drinks
You can take topiramato with or without food. Drink plenty of fluids during the day to prevent kidney stone formation while taking topiramato. You should avoid drinking alcohol while taking topiramato.
Pregnancy and breastfeeding
Important advice for fertile women:
Topiramato cinfa may cause harm to a baby during pregnancy. If you are a fertile woman, consult your doctor about other possible treatments. Visit your doctor to review your treatment and discuss the risks at least once a year.
Prevention of migraines:
Treatment of epilepsy:
Risks of topiramato during pregnancy (regardless of the condition for which topiramato is used):
There is a risk of harm to the baby during pregnancy if topiramato cinfa is used during pregnancy.
Need for contraceptive methods for fertile women:
Use of topiramato cinfa in girls:
If you are the parent/caregiver of a girl treated with topiramato cinfa, you should consult your doctor immediately once your daughter experiences her first menstrual period (menarche). The doctor will inform you about the risks to a baby during pregnancy due to exposure to topiramato during pregnancy and about the need to use highly effective contraceptive methods.
If you want to become pregnant while taking topiramato cinfa:
If you have become pregnant or think you may be pregnant while taking topiramato cinfa:
Make sure to read the patient guide that your doctor will give you.
A patient information card is provided with the packaging of topiramato cinfa to remind you of the risks of topiramato during pregnancy.
Breastfeeding
The active ingredient of topiramato cinfa (topiramato) passes into breast milk. Side effects have been observed in breastfed babies of mothers treated with topiramato, including diarrhea, drowsiness, irritability, and low weight gain. Therefore, your doctor will discuss with you whether to stop breastfeeding or whether to stop the treatment with topiramato. Your doctor will take into account the importance of the benefits for the mother and the risk to the baby. Mothers who are breastfeeding and taking topiramato should inform their doctor as soon as possible if the baby experiences anything unusual.
Driving and operating machines
Topiramato may cause symptoms such as drowsiness, dizziness, or visual disturbances, and may decrease your reaction time. These effects, as well as the underlying condition, may impair your ability to drive vehicles or operate machines. Therefore, do not drive, operate machines, or engage in other activities that require special attention until your doctor evaluates your response to this medication.
topiramato cinfa contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.
Girls and fertile women:
Topiramato cinfa treatment should start and continue under the supervision of an experienced doctor in the treatment of epilepsy or migraine. Visit your doctor to review your treatment at least once a year.
If you take more topiramato cinfa than you should
You may experience an overdose if you are taking another medication with topiramato.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, Phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take topiramato cinfa
If you interrupt the treatment with topiramato cinfa
Do not stop treatment without your doctor's instructions. Your symptoms may reappear. If your doctor decides that you should stop taking this medication, they will gradually reduce your dose over several days.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Consult your doctor or seek medical attention immediately if you experience the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from available data)
Other side effects include the following, if severe, please consult your doctor or pharmacist:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Frequency not known (cannot be estimated from available data)
Other side effects in children
Generally, side effects observed in children are similar to those observed in adults, but the following side effects may be more common in children than in adults:
Other side effects that may appear in children are:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25°C.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. In this way, you will help protect the environment.
Composition of topiramate cinfa
Each film-coated tablet of topiramate cinfa contains 100 mg of topiramate.
Tablet core: mannitol, pregelatinized cornstarch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica, and magnesium stearate.Covering layer:opadry II yellow 85G32313 (polyvinyl alcohol, talc, titanium dioxide (E-171), macrogol, soy lecithin (E-322), and yellow iron oxide (E-172)).
Appearance of the product and contents of the package
Yellow, cylindrical, film-coated, biconvex tablets with the code “V4” on one face.
It is presented in aluminum/aluminum blisters or HDPE bottles with LDPE caps.
Each package contains 60 film-coated tablets.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) - Spain
Responsible manufacturer:
BALKANPHARMA DUPNITSA AD
3 Samokovsko Shosse Str., Dupnitsa 2600 - Bulgaria
or
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) - Spain
Last review date of this leaflet:January 2024
Other sources of information
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/69137/P_69137.html
QR code to:https://cima.aemps.es/cima/dochtml/p/69137/P_69137.html
The most recent approved information about the patient guide for this medicine is available by scanning the following QR code with a smartphone. The same information is also available on the following webpage(3252 (aemps.es)):
QR code to:3252 (aemps.es)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.